Vivani Medical to Showcase at the Emerging Growth Conference
Vivani Medical, Inc. (NASDAQ: VANI), known for its pioneering work in biopharmaceutical innovation, has announced it will take part in the upcoming Emerging Growth Conference. This event presents a great opportunity for investors and stakeholders to learn more about Vivani's groundbreaking methods of drug delivery through cutting-edge implant technology.
Engaging Presentation for All Investors
Vivani invites individual and institutional investors, as well as financial advisors and analysts, to join an interactive online presentation. Scheduled for 1:10 p.m. Eastern Time, this live event will feature insights from the Company’s President and CEO, Adam Mendelsohn, Ph.D. He will discuss Vivani's vision and mission, followed by a Q&A session to address any questions from the audience directly.
Revolutionary Technology and Its Influence
Vivani Medical is widely recognized for its cutting-edge technology, which includes miniaturized, ultra-long-acting drug implants. These advanced devices are designed to consistently deliver medication over extended periods, promoting higher adherence to treatment plans, especially for chronic conditions. This novel drug delivery system aims to greatly enhance patient experiences by reducing the frequency of required dosing, thus improving overall treatment effectiveness.
Overview of the Product Pipeline
Vivani's flagship product, NPM-115, features a small implant designed for six months of administering GLP-1 (exenatide) to help manage chronic weight for individuals dealing with obesity. This product stands out by providing a reliable medication delivery solution, effectively addressing the common challenges associated with non-adherence.
Alongside NPM-115, Vivani is developing the NPM-139 implant, which utilizes semaglutide tailored to similar patient groups. This innovative implant has the potential to require administration only once a year, making it particularly attractive for patients seeking convenient treatment options. Additionally, the NPM-119 program targets Type 2 Diabetes management through a six-month subdermal exenatide implant, presenting a well-rounded approach to treating chronic diseases.
The Significance of Adherence in Treatment
Medication non-adherence is a worrying issue in healthcare, affecting about 50% of patients, particularly those with chronic diseases. This problem results in over $500 billion in avoidable healthcare costs in the U.S. each year, alongside a notable number of preventable deaths. Vivani understands this critical issue and designs its products to ensure that patients can fully benefit from their medications. By alleviating the daily burden of oral or injectable medications, Vivani aims to create a treatment experience that not only supports adherence but also contributes to achieving meaningful health outcomes.
Tackling a Growing Market
With the competitive landscape for GLP-1 therapies expanding—over 50 new molecular entities are in clinical development—Vivani Medical sets itself apart with its portfolio of long-acting implants. This distinctive capability allows Vivani to provide significant therapeutic options for patients, prescribers, and payers, opening a promising path for growth and advancement in the biopharmaceutical industry.
A Look at Cortigent, Inc.
Vivani's commitment to innovation extends beyond pharmaceuticals, encompassing its wholly-owned subsidiary, Cortigent, Inc. Cortigent specializes in developing precise neurostimulation systems designed to restore essential body functions for those with mobility impairments. Their flagship investigational devices include Orion®, aimed at offering artificial vision for profoundly blind individuals, and an innovative system to support recovery for those who are partially paralyzed due to stroke. Additionally, Cortigent has launched the Argus II® visual prosthetic device, which has already demonstrated the ability to restore meaningful vision.
Strategic Aspirations for Advancement
Vivani Medical is focused on exploring various strategic options to advance Cortigent's groundbreaking technology. The combination of biopharmaceutical progress with innovative neural assistance technology showcases Vivani's comprehensive approach to addressing diverse health challenges. Through these initiatives, the company aims to establish itself as a leader in both drug delivery and neurological recovery solutions.
Frequently Asked Questions
What is Vivani Medical known for?
Vivani Medical is known for its innovative biopharmaceutical implants that provide long-lasting drug delivery, enhancing adherence to treatment plans.
When will Vivani present at the Emerging Growth Conference?
Vivani is set to present at the conference on September 25, 2024, at 1:10 p.m. Eastern Time.
How do Vivani's implants enhance medication adherence?
The implants are designed to deliver medication over an extended period, minimizing the need for daily or weekly dosing and thereby improving adherence.
What are the key products in Vivani's product pipeline?
Key products include NPM-115 and NPM-139 for chronic weight management, along with NPM-119 for managing Type 2 Diabetes.
What does Cortigent, Inc. focus on?
Cortigent is a subsidiary of Vivani that develops neurostimulation systems aimed at restoring bodily functions, including vision rehabilitation.
